

This material is an English translation of the press release announced on December 19, 2016 in Japanese, and the Japanese release is given priority about the content and the interpretation.

December 19, 2016

**Notification of application for manufacturing and marketing approval of HP-3060 in Japan
(a transdermal system for the treatment of allergic rhinitis)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) announces that it has filed an application for new drug approval with Ministry of Health, Labor and Welfare for a transdermal drug for the treatment of allergic rhinitis in Japan (Development code: HP-3060, Active pharmaceutical ingredient: emedastine fumarate, hereinafter referred to as “the product”).

The product is a systemic transdermal tape formulation developed by utilizing Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu expects it to be a new option for the treatment of allergic rhinitis by realizing its long-lasting effect by means of maintaining a stable blood drug concentration.

Hisamitsu aims to acquire for manufacturing and marketing approval during FY 2017.